samedan logo
home > pmps > summer 2003 > making the best possible use of an industrial freeze drier
Pharmaceutical Manufacturing and Packing Sourcer

Making the Best Possible Use of an Industrial Freeze Drier

This article investigates measures that can be taken to ensure that industrial freeze dryers remain competitive in the field of freeze-dried medicine production after 15 years of intensive use and still operate at the highest European standards.
The Production Line

For the aseptic filling and freeze drying of bottled products the following steps can be taken:

Wash on FAW1000 Bausch and Ströbel
Sterilisation/depyrogenation in radiant tunnel DST4047 Bausch and Ströbel
Filling KSF1020 Bausch and Ströbel
Freeze drying in Cirp CS60/6
- Classic on KS1020 Bausch and Ströbel
- Special on Marchesini ML657
- Technical data
- capacity to deal with bottles ranging from the standard 2R to the standard 30R to a maximal actual cadence of 3,600 bottles per hour
Environment: A, B, A/B classes according to the European Guide of the Good Practices of Manufacture (capping in A class)

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

By M Roubertou Jean-Yves, Head Pharmacist and General Manager at Elaiapharm

Mr Roubertou has been Head Pharmacist and Managing Director of the Elaiapharm Laboratory, a company manufacturing dry, sterile and liquid forms, since 2000. He was awarded a diploma by the Faculty of Pharmacy of the University of Paris and had special basic school-leaving qualification of biology and an engineering degree in biotechnology at the University of Rennes. He is a qualified Pharmacist.

His career in biochemistry began in the hospitals of Paris before he became Director of a hospital-based laboratory of biochemistry. After 10 years of hospital-based work, Mr Roubertou began an industrial career with responsibility for the control and development of the laboratory before becoming Head Pharmacist at Panpharma Laboratory, specialising in the aseptic distribution of parenteral powders.

M Roubertou Jean-Yves
Print this page
Send to a friend
Privacy statement
News and Press Releases

Significant improvement in overall survival with ERLEADA®▼ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer

BEERSE, BELGIUM, May 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA®▼ (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.1 Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Programme (Abstract #5516) beginning on Friday 29th May.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach


In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement